Bavarian Nordic presents new preclinical data for Covid-19 vaccine
Bavarian Nordic's first clinical studies with a vaccine for Covid-19 are almost ready. Ahead of launch, the firm has received a batch of positive preclinical data. This confirms the potential, according to Bavarian Nordic's CEO Paul Chaplin.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Bavarian Nordic is getting ready for its first in-human trial with the vaccine, which the firm in-licensed from Adaptvac, and now, in the first round, new data has arrived.